Bank of America’s Kyntra Bio KYNB Stock Holding History

Bank of America’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-388	Closed	-$360K	–	7524
2020 Q4	$360K	Hold	388	–	–	﹤0.01%	5220
2020 Q3	$399K	Hold	388	–	–	﹤0.01%	4883
2020 Q2	$393K	Sell	388 -84	-18%	-$78K	﹤0.01%	4787
2020 Q1	$410K	Buy	+472	New	+$469K	﹤0.01%	4642

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Bank of America's KYNB Position: Q1 2026 in Review

Bank of America sold out of Kyntra Bio (KYNB) in Q1 2026, closing a stake of 595 shares — an estimated $5.22K sold.

Bank of America first reported a position in KYNB in Q4 2014 and held it in 45 quarters. The position peaked at $23M in Q1 2019. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.

Bank of America reported no remaining Kyntra Bio position as of Q1 2026 after selling out during the quarter.
Bank of America sold 595 Kyntra Bio shares in Q1 2026, an estimated $5.22K.
Bank of America first reported a position in Kyntra Bio in Q4 2014 and held it in 45 quarters.
Bank of America's Kyntra Bio position peaked at $23M in Q1 2019.
32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.